Tangier disease: Difference between revisions
No edit summary |
|||
| Line 26: | Line 26: | ||
==Pathophysiology== | ==Pathophysiology== | ||
High-density lipoproteins are created when a protein in the bloodstream, apolipoprotein A1 (apoA1), combines with cholesterol and phospholipids. The cholesterol and phospholipids used to form HDL originate from inside cells but is transported out of the cell into the blood via the [[ABCA1]] transporter. People with Tangier disease have defective [[ABCA1]] transporters resulting in a greatly reduced ability to transport cholesterol out of their cells, which leads to an accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as [[hypoalphalipoproteinemia]]. | [[High-density lipoproteins]] are created when a protein in the bloodstream, [[apolipoprotein A1]] ([[apoA1]]), combines with [[cholesterol]] and phospholipids. The cholesterol and phospholipids used to form HDL originate from inside cells but is transported out of the cell into the blood via the [[ABCA1]] transporter. People with Tangier disease have defective [[ABCA1]] transporters resulting in a greatly reduced ability to transport cholesterol out of their cells, which leads to an accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as [[hypoalphalipoproteinemia]]. | ||
===Genetics=== | ===Genetics=== | ||
[[Image:autorecessive.svg|thumb|left|120px|Tangier disease has an [[Recessive gene|autosomal recessive]] pattern of inheritance.]] | [[Image:autorecessive.svg|thumb|left|120px|Tangier disease has an [[Recessive gene|autosomal recessive]] pattern of inheritance.]] | ||
This condition is inherited in an [[autosomal recessive]] pattern, which means both copies of the gene in each cell have | This condition is inherited in an [[autosomal recessive]] pattern, which means both copies of the [[gene]] in each cell have [[mutation]]s. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. | ||
[[Mutation]]s in the chromosome 9q31 lead to a defective ''[[ABCA1]]'' transporter. These mutations prevent the [[ABCA1]] protein from effectively transporting cholesterol and phospholipids out of cells for pickup by ApoA1 in the bloodstream. | [[Mutation]]s in the chromosome 9q31 lead to a defective ''[[ABCA1]]'' transporter. These mutations prevent the [[ABCA1]] protein from effectively transporting cholesterol and phospholipids out of cells for pickup by ApoA1 in the bloodstream. | ||
This inability to transport cholesterol out of cells leads to a deficiency of high-density lipoproteins in the circulation, which is a risk factor for coronary artery disease. | This inability to transport cholesterol out of cells leads to a deficiency of high-density lipoproteins in the circulation, which is a risk factor for [[coronary artery disease]] ([[CAD]]). | ||
Additionally, the buildup of cholesterol in cells can be toxic, causing cell death or impaired function. These combined factors lead to the signs and symptoms of Tangier disease. | Additionally, the buildup of cholesterol in cells can be toxic, causing cell death or impaired function. These combined factors lead to the signs and symptoms of '''Tangier disease'''. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Revision as of 20:06, 31 July 2012
| Tangier disease | |
| ICD-10 | E78.6 |
|---|---|
| ICD-9 | 272.5 |
| OMIM | 205400 |
| DiseasesDB | 12901 |
| MeSH | D013631 |
|
WikiDoc Resources for Tangier disease |
|
Articles |
|---|
|
Most recent articles on Tangier disease Most cited articles on Tangier disease |
|
Media |
|
Powerpoint slides on Tangier disease |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tangier disease at Clinical Trials.gov Trial results on Tangier disease Clinical Trials on Tangier disease at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tangier disease NICE Guidance on Tangier disease
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tangier disease Discussion groups on Tangier disease Patient Handouts on Tangier disease Directions to Hospitals Treating Tangier disease Risk calculators and risk factors for Tangier disease
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tangier disease |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Tangier disease is a rare inherited disorder characterized by a severe reduction in the amount of high-density lipoprotein (HDL), often referred to as "good cholesterol," in the bloodstream. High-density lipoproteins are created when a type of protein in the bloodstream, apolipoprotein A1 (apoA1), picks up cholesterol from the cells. People with Tangier disease have a greatly reduced ability to transport cholesterol out of their cells, leading to a deficiency of high-density lipoproteins in the bloodstream and the accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as hypolipoproteinemia.
People affected by this condition also have slightly elevated amounts of fat in the blood (mild hypertriglyceridemia) and disturbances in nerve function (neuropathy). The tonsils are visibly affected by this disorder; they frequently appear orange or yellow and are extremely enlarged. Affected people often develop premature atherosclerosis, which is characterized by fatty deposits and scar-like tissue lining the arteries. Other signs of this condition may include an enlarged spleen (splenomegaly), an enlarged liver (hepatomegaly), clouding of the clear covering of the eye (cornea), and early-onset cardiovascular disease.
Historical Perspective
Tangier disease (TD) is a genetic disorder of cholesterol transport named for the secluded island of Tangier, located off the coast of Virginia. TD was first identified in a five-year-old inhabitant of the island who had characteristic orange tonsils, very low levels of high density lipoprotein (HDL) or 'good cholesterol', and an enlarged liver and spleen.
Pathophysiology
High-density lipoproteins are created when a protein in the bloodstream, apolipoprotein A1 (apoA1), combines with cholesterol and phospholipids. The cholesterol and phospholipids used to form HDL originate from inside cells but is transported out of the cell into the blood via the ABCA1 transporter. People with Tangier disease have defective ABCA1 transporters resulting in a greatly reduced ability to transport cholesterol out of their cells, which leads to an accumulation of cholesterol in many body tissues. Reduced blood levels of high-density lipoproteins is sometimes described as hypoalphalipoproteinemia.
Genetics
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Mutations in the chromosome 9q31 lead to a defective ABCA1 transporter. These mutations prevent the ABCA1 protein from effectively transporting cholesterol and phospholipids out of cells for pickup by ApoA1 in the bloodstream.
This inability to transport cholesterol out of cells leads to a deficiency of high-density lipoproteins in the circulation, which is a risk factor for coronary artery disease (CAD).
Additionally, the buildup of cholesterol in cells can be toxic, causing cell death or impaired function. These combined factors lead to the signs and symptoms of Tangier disease.
Epidemiology and Demographics
- Tangier disease is a rare disorder with approximately 50 cases identified worldwide.
- This disorder was originally discovered on Tangier Island off the coast of Virginia, but has now been identified in people from many different countries.
Diagnosis
People affected by this condition also have slightly elevated amounts of fat in the blood (mild hypertriglyceridemia) and disturbances in nerve function (neuropathy). The tonsils are visibly affected by this disorder; they frequently appear orange or yellow and are extremely enlarged. Affected people often develop premature atherosclerosis, which is characterized by fatty deposits and scar-like tissue lining the arteries. Other signs of this condition may include an enlarged spleen (splenomegaly), an enlarged liver (hepatomegaly), clouding of the cornea, and early-onset cardiovascular disease.
References
External links
- Tangier disease at NLM Genetics Home Reference
de:Tangier-Krankheit it:Malattia di Tangier nl:Ziekte van Tangier